Legislation requiring biologic and biosimilar manufacturers to report biosimilar patent litigation settlements to the Department of Justice and Federal Trade Commission in the same manner as drug patent settlements is now heading to President Trump's desk as part of the Patient Right to Know Act.
Pay-for-delay reporting for generics has been required for several years under the Medicare Modernization Act of 2003. The FTC uses...